(Q43680261)

25 November 2017

title

Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre (English)

1 reference

25 November 2017

main subject

arterial hypertension

1 reference

1

1 reference

25 November 2017

author name string

Marcus T R Roofthooft

2

1 reference

25 November 2017

Rosa L E Van Loon

3

1 reference

25 November 2017

Mark-Jan Ploegstra

4

1 reference

25 November 2017

Beatrijs Bartelds

5

1 reference

25 November 2017

Hans L Hillege

6

1 reference

25 November 2017

Rolf M F Berger

7

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 February 2014

1 reference

25 November 2017

1 reference

25 November 2017

volume

100

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

224-230

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Childhood idiopathic pulmonary arterial hypertension: a national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Test-retest reliability of the 6-minute walk test in individuals with Down syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304895

10.1136/HEARTJNL-2013-304895

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference